Unsupervised [<sup>18</sup>F]Flortaucipir cutoffs for tau positivity and staging in Alzheimer's disease.
Where this comes from
- Record sourced from PubMed, PMID 37272955.
- Also identified by DOI 10.1007/s00259-023-06280-7 and PMC identifier 10542510.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Several [<sup>18</sup>F]Flortaucipir cutoffs have been proposed for tau PET positivity (T<sup>+</sup>) in Alzheimer's disease (AD), but none were data-driven. The aim of this study was to establish and validate unsupervised T<sup>+</sup> cutoffs by applying Gaussian mixture models (GMM). Amyloid negative (A<sup>-</sup>) cognitively normal (CN) and amyloid positive (A<sup>+</sup>) AD-related dementia (ADRD) subjects from ADNI (n=269) were included. ADNI (n=475) and Geneva Memory Clinic (GMC) cohorts (n=98) were used for validation. GMM-based cutoffs were extracted for the temporal meta-ROI, and validated against previously published cutoffs and visual rating. GMM-based cutoffs classified less subjects as T<sup>+</sup>, mainly in the A<sup>-</sup> CN (<3.4% vs >28.5%) and A<sup>+</sup> CN (<14.5% vs >42.9%) groups and showed higher agreement with visual rating (ICC=0.91 vs ICC<0.62) than published cutoffs. We provided reliable data-driven [<sup>18</sup>F]Flortaucipir cutoffs for in vivo T<sup>+</sup> detection in AD. These cutoffs might be useful to select participants in clinical and research studies.
Medical subject headings
- Alzheimer Disease
- Cognitive Dysfunction